CAPGEMINI overview

CAPGEMINI Société Européenne (European Company) with a share capital of €1,370,779,768 Registered office at 11, rue de Tilsitt, 75017 Paris (France) 330 703 844 RCS Paris Paris, March 21, 2025. Combined Shareholders’ Meeting on May 7 th , 2025 Availability of documents relating to the General Meeting The Capgemini SE Combined Shareholders’ Meeting will be held on Wednesday, May 7, 2025 at 2 p.m . CET at Pavillon Gabriel, 5 avenue Gabriel, Paris (8 th District). Documents and information...

CAPGEMINI Société Européenne (European Company) with a share capital of €1,370,779,768 Registered office at 11, rue de Tilsitt, 75017 Paris (France) 330 703 844 RCS Paris Paris, March 21, 2025. Publication of the 2024 Universal Registration Document Capgemini SE filed today with the French Financial Markets Authority (AMF) its 2024 Universal Registration Document (“ Document d’Enregistrement Universel” ), which does include the following documents: the 2024 annual financial report,...

Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leading provider of high-performance lidar sensors and solutions, today announced its expansive growth during 2024 in the smart infrastructure vertical across intelligent transportation systems, logistics, crowd analytics, and security. Ouster increased its software-attached bookings 1 by over 60% year-over-year, which is expected to increase the Company's cumulative software deployments to more than 700 sites. Demand for...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study,...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME ( PR econditioning IM munostimulatory E valuation) Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US-based, multi-site, placebo-controlled study will enroll up to forty...

Salesforce and Google today announced a major expansion of their strategic partnership, delivering choice in the models and capabilities businesses use to build and deploy AI-powered agents . In today's constantly evolving AI landscape, innovations like autonomous agents are emerging so quickly that businesses struggle to keep pace. This expanded partnership provides crucial flexibility, empowering customers to develop tailored AI solutions that meet their specific needs, rather than being...

App Orchid, a Google Cloud Cortex Framework partner, will enable customers to ask natural language questions and get AI-powered insights from enterprise data grounded with Cortex Framework SAN RAMON, CA / ACCESS Newswire / February 5, 2025 / App Orchid , a leader in making data actionable with Artificial Intelligence (AI), today announced that it has expanded its collaboration with Google Cloud to provide supporting Google Cloud Cortex Framework deployments, accelerating business decisions and...